Last reviewed · How we verify
AP 12009 80 µM
AP 12009 80 µM is an anti-PD-1 monoclonal antibody.
AP 12009 80 µM is an anti-PD-1 monoclonal antibody. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | AP 12009 80 µM |
|---|---|
| Sponsor | Isarna Therapeutics GmbH |
| Drug class | anti-PD-1 monoclonal antibody |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby unleashing an anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Hypothyroidism
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AP 12009 80 µM CI brief — competitive landscape report
- AP 12009 80 µM updates RSS · CI watch RSS
- Isarna Therapeutics GmbH portfolio CI